Status:
COMPLETED
Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection
Lead Sponsor:
Novartis
Conditions:
Chickenpox
Herpes Zoster
Eligibility:
All Genders
1-12 years
Phase:
PHASE3
Brief Summary
Varicella zoster virus causes chickenpox in children and shingles in adults. Chickenpox is usually a self-limiting illness characterized by fever and a rash. Serious complications can include secondar...
Eligibility Criteria
Inclusion
- Male or female children 1-12 years of age
- Clinical or laboratory evidence of varicella zoster infection
- Patients suspected of having varicella zoster infection
Exclusion
- Patients unable to swallow
- Concomitant use of probenecid
- Positive pregnancy
- Additional protocol-defined inclusion/exclusion criterial may apply. For detailed information on eligibility, please contact the study center nearest to you (see below), or call the following number 1-862-778-3544 or 1-434-951-3228
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2007
Estimated Enrollment :
76 Patients enrolled
Trial Details
Trial ID
NCT00098046
Start Date
July 1 2005
End Date
July 1 2007
Last Update
September 26 2007
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Columbia University Medical Center
New York, New York, United States, 10032
2
Novartis Investigational Site
San José, Costa Rica
3
Novartis Investigational Site
Cuidad de Guatemala, Guatemala
4
Novartis Investigational Site
David, Chiriqui, Panama